Hemoglobinopathy: Difference between revisions
Line 23: | Line 23: | ||
[[2,3-Bisphosphoglycerate|2,3 BPG]]<br>• [[Carboxyhemoglobin|Carboxyhemoglobinemia]], [[Myoglobin|HbCO]]<br>• Structural variants |E19=[[Congenital]] [[Methemoglobinemia|methemoglobinemia]]<br>• Structural variants<br>• [[Cytochrome b5 reductase|Cytochrome b5 reductase]] [[Deficiency|deficiency]] |E20=Nonenzymatic [[Glycosylation|glycosylation]] | | |}} | [[2,3-Bisphosphoglycerate|2,3 BPG]]<br>• [[Carboxyhemoglobin|Carboxyhemoglobinemia]], [[Myoglobin|HbCO]]<br>• Structural variants |E19=[[Congenital]] [[Methemoglobinemia|methemoglobinemia]]<br>• Structural variants<br>• [[Cytochrome b5 reductase|Cytochrome b5 reductase]] [[Deficiency|deficiency]] |E20=Nonenzymatic [[Glycosylation|glycosylation]] | | |}} | ||
{{familytree | |!| | | | | |!| |!| | | | | |!| | | | | |!| | | | | |!| | | | | |!| | | | | | |!|}} | {{familytree | |!| | | | | |!| |!| | | | | |!| | | | | |!| | | | | |!| | | | | |!| | | | | | |!|}} | ||
{{familytree |boxstyle=text-align: left; | |!| | | | | |!| |!| | | | | |!| | | | | |!| | | | | |`| E18 | | |`| E24 | | | |)| E21 |E18=Low/decreased oxygen [[Chemical affinity|affinity]] states<br>• [[2,3-Bisphosphoglycerate|2,3 BPG]]<br>• Structural variants |E21=Amino-terminal | {{familytree |boxstyle=text-align: left; | |!| | | | | |!| |!| | | | | |!| | | | | |!| | | | | |`| E18 | | |`| E24 | | | |)| E21 |E18=Low/decreased oxygen [[Chemical affinity|affinity]] states<br>• [[2,3-Bisphosphoglycerate|2,3 BPG]]<br>• Structural variants |E21=Amino-terminal acetylation |E24=Acquired ([[Toxicity|toxic]]) [[Methemoglobinemia|methemoglobinemia]] | |}} | ||
{{familytree | |!| | | | | |!| |!| | | | | |!| | | | | |!| | | | | | | | | | | | | | | | | | |!|}} | {{familytree | |!| | | | | |!| |!| | | | | |!| | | | | |!| | | | | | | | | | | | | | | | | | |!|}} | ||
{{familytree |boxstyle=text-align: left; | |`| E02 | | |!| |`| E05 | | |)| E08 | | |`| E14 | | | | | | | | | | | | | | | |)| E22 | | |E02=Nondeletion mutants<br>• [[Hemoglobin|Hb]] Constnt Spring<br>• Other |E05=[[Thalassemia|α-Thalassemia]] associated with [[Myelodysplastic syndrome|myelodysplastic syndromes]] (ATMDS) <br>• Due to [[mutations]] of the [[ATRX|ATRX]] [[gene]]|E08=SS, [[Sickle-cell disease|sickle cell anemia/disease]] |E14=[[Acquired disorder|Acquired]] [[Instability|instability]]—[[Oxidant|oxidant]] [[Hemolysis|hemolysis]]<br>• Drug-induced<br>• [[Glucose-6-phosphate dehydrogenase deficiency|G6PD deficiency]]|E22=Amino-terminal carbamylation | | |}} | {{familytree |boxstyle=text-align: left; | |`| E02 | | |!| |`| E05 | | |)| E08 | | |`| E14 | | | | | | | | | | | | | | | |)| E22 | | |E02=Nondeletion mutants<br>• [[Hemoglobin|Hb]] Constnt Spring<br>• Other |E05=[[Thalassemia|α-Thalassemia]] associated with [[Myelodysplastic syndrome|myelodysplastic syndromes]] (ATMDS) <br>• Due to [[mutations]] of the [[ATRX|ATRX]] [[gene]]|E08=SS, [[Sickle-cell disease|sickle cell anemia/disease]] |E14=[[Acquired disorder|Acquired]] [[Instability|instability]]—[[Oxidant|oxidant]] [[Hemolysis|hemolysis]]<br>• Drug-induced<br>• [[Glucose-6-phosphate dehydrogenase deficiency|G6PD deficiency]]|E22=Amino-terminal carbamylation | | |}} |
Revision as of 14:50, 13 September 2018
Hemoglobinopathy Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Hemoglobinopathy is a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule. Most common hemoglobinopathies include sickle-cell disease.The renge of clinical manifestations of the hemoglobinopathies are from mild hypochromic anemia to moderate hematological disease to severe.
Classification
Hemoglobinopathy be classified according to genetic and structure of hemoglobin into two main groups:[1]
The range of clinical manifestations of the hemoglobinopathies are from mild hypochromic anemia to moderate hematological disease to severe.
Epidemiology and Demographics
Prevalence
- In 2008, the prevalence of hemoglobinopathy was estimated to be 7% of the worldwide population being carrier.[2]
- The most prevalance of hemoglobinopathy gene carriers in the world's are in South-East Asia(up to 70%) and Arab nations(up to 60).[2]
- In Russia is seen rare[2]
- Recent years it is increased in Germany.[3]
Race
α-thalassemias
It occure cur mainly in Africa, Arab nations, and, more frequently and South-East Asia.[4]
β-thalassemias
It occure cur mainly in Mediterranean countries, South-East Europe, Arab nations and Asia.[5]
Diagnosis
Hemoglobin testing(hemoglobin electrophoresis or chromatography) , [[Red blood cell
|red blood cell]] count, hemoglobin pattern, cardinal symptoms[6]
History & clinical symptoms | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Blood test | hemolysate | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of abnormal hemoglobins | Diagnosis of β-thalassemia | Diagnosis of α-thalassemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alkaline electrophoresis • acid electrophoresis •HPLC | Electrophoresis HPLC • HbA2,Hbf | electrophoresis HPLC • DNA testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evidence of abnormality,comparison of mobility with that of known abnormalities, if HBS suspected: solubility test | Separation/quantification | Evalution of all data and findings | Evalution of all data and findings | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnisis of | Dignisis of α-thalassemia | {{{β-thalassemia }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNA sequencing if needed | DNA sequencing if needed(thalassemia major, thalassemia intermedia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evaluation of all data and findings(including blood count ethnic and origin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of hemoglobinopathy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Forget BG, Bunn HF (February 2013). "Classification of the disorders of hemoglobin". Cold Spring Harb Perspect Med. 3 (2): a011684. doi:10.1101/cshperspect.a011684. PMC 3552344. PMID 23378597.
- ↑ 2.0 2.1 2.2 Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Cario H, Stahnke K, Sander S, Kohne E (January 2000). "Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study". Ann. Hematol. 79 (1): 7–12. PMID 10663615.
- ↑ Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Herklotz R, Risch L, Huber AR (January 2006). "[Hemoglobinopathies--clinical symptoms and diagnosis of thalassemia and abnormal hemoglobins]". Ther Umsch (in German). 63 (1): 35–46. doi:10.1024/0040-5930.63.1.35. PMID 16450733.